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Steroidogenic acute regulatory protein (StAR) mediates the rate-limiting step in the synthesis of steroid hor-
mones, essential to fetal development. We have reported that the StAR expression in fetal adrenal is inhibited
in a rat model of nicotine-induced intrauterine growth retardation (IUGR). Here using primary human fetal
adrenal cortex (pHFAC) cells and a human fetal adrenal cell line NCI-H295A, we show that nicotine inhibits
StAR expression and cortisol production in a dose- and time-dependent manner, and prolongs the inhibitory
effect on cells proliferating over 5 passages after termination of nicotine treatment. Methylation detection
within the StAR promoter region uncovers a single site CpG methylation at nt -377 that is sensitive to nico-
tine treatment. Nicotine-induced alterations in frequency of this point methylation correlates well with the
levels of StAR expression, suggesting an important role of the single site in regulating StAR expression. Fur-
ther studies using bioinformatics analysis and siRNA approach reveal that the single CpG site is part of the
Pax6 binding motif (CGCCTGA) in the StAR promoter. The luciferase activity assays validate that Pax6 in-
creases StAR gene expression by binding to the glucagon G3-like motif (CGCCTGA) and methylation of this
site blocks Pax6 binding and thus suppresses StAR expression. These data identify a nicotine-sensitive CpG
site at the Pax6 binding motif in the StAR promoter that may play a central role in regulating StAR expression.
The results suggest an epigenetic mechanism that may explain how nicotine contributes to onset of adult dis-
eases or disorders such as metabolic syndrome via fetal programming.
© 2011 Elsevier Inc. All rights reserved.
Introduction
Maternal cigarette smoking is the single largest modifiable risk
factor attributable to intrauterine growth retardation (IUGR), which
is defined as being less than 10th percentile of the body size distribu-
tion for a gestational age (Delpisheh et al., 2008; Hofman et al., 1997).
Among more than 2000 compounds released from smoking, nicotine
is the major aversive substance that perturbs fetal growth and devel-
opment (Petre et al., 2011; Yildiz, 2004). Increasing epidemiological
evidence supports the notion that adverse events in fetal life such
as IUGR permanently alter the structure and physiology of the adult
offspring, a phenomenon dubbed “fetal programming” (Guilloteau
et al., 2009; Habib et al., 2011). In addition, prenatal nicotine expo-
sure is associated with increased risk of IUGR and susceptibility to
adult diseases, particularly cardiovascular diseases and metabolic
syndrome (Feng et al., 2010; Geelhoed et al., 2011; Pellanda et al.,
2009).
Fetal programming of key endocrine systems, especially the
hypothalamic–pituitary–adrenal (HPA) axis, has beenproposed as a po-
tential intermediary that links IUGR to adult metabolic dysfunction
(Kanaka-Gantenbein, 2010; Xita and Tsatsoulis, 2010). Long term con-
sequences of low birth weight on adrenal cortisol secretion contribute
to increased risks for the metabolic syndrome in later life, suggesting
a central role for adrenocortical steroidogenesis in intrauterine fetal
programming (Marciniak et al., 2011; Ong, 2005). Like adult, human
fetal adrenal expresses the rate-limiting enzyme of steroidogenesis—
acute regulatory protein (StAR) and cytochrome P450 cholesterol side
chain cleavage (P450scc), which is essential for the production of ste-
roid hormones including cortisol, aldosterone, dehydroepiandrosterone
sulfate (DHEAS), etc. (Wang et al., 2006). StAR mediates the transloca-
tion of cholesterol from the outer to the inner mitochondrial
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membrane, which is the initial and rate-limiting step in adrenocortical
steroid biosynthesis, while P450scc cleaves the cholesterol side chain,
converting cholesterol to pregnenolone, the precursor of steroid hor-
mones (Miller and Auchus, 2011; Stocco, 2001). Our previous studies
have shown that fetal adrenal could be an important xenobiotic-me-
tabolizing organ in fetal development and may play a potential role
in xenobiotic-induced fetal development toxicity (Wang et al., 2008).
Furthermore, our results have shown that prenatal exposure to nico-
tine as well as ethanol can inhibit adrenal StAR expression and induce
IUGR in fetal rats (Chen et al., 2007; Liang et al., 2010). However, the
underlyingmechanism concerning how nicotine alters StAR expression
in fetal adrenal remains unknown.
Experimental data in rodents and recent observations in humans
suggest that epigenetic changes in growth-related genes play a signif-
icant role in fetal programming (Gicquel et al., 2008; Martinez-
Arguelles and Papadopoulos, 2010). DNA methylation as the major
epigenetic modification persists throughout the process of fertiliza-
tion and embryo development. The patterns of DNA methylation are
heritable marks that ensure accurate transmission of the chromatin
states and gene expression profiles over many cell generations. As al-
terations of DNA methylation are stable in tissues and body fluids are
suitable for sensitive detection, DNA methylation changes may serve
as molecular biomarkers for disease diagnosis and therapeutic out-
come (Deng et al., 2010). Studies have shown that aberrant DNA
methylation occurs in human adrenocortical tumorigenesis that is
often accompanied by abnormal hormone production (Liu et al.,
2004). Maternal nicotine exposure increases fetal incidence of adult
cardiomyopathy, which has a direct relationship with abnormal regu-
lated gene expression caused by the altered pattern of DNA methyla-
tion (Meyer and Lubo, 2007). In addition, evidence has shown that
DNA methylation inhibitor 5-aza-2′-deoxycytidine (Azad) affects
StAR expression and cortisol secretion in human adrenocortical NCI-
H295R cells (Liu et al., 2004). Therefore, DNA methylation may
mediate how nicotine alters StAR expression in fetal adrenal, which
increases the susceptibility to adult metabolic syndrome.
Although numerous publications regarding the mechanisms of
nicotine-induced IUGR are available in the literature, the direct toxicity
of nicotine on fetal adrenal is poorly understood, as are the inheritable
epigenetic mechanisms that are responsible for fetal programming.
We have shown that in a nicotine-induced IUGR rat model the expres-
sion of StAR and P450scc increases in the maternal adrenals, but
decreases in the fetal adrenals (Chen et al., 2007). In this study, primary
human fetal adrenal cortex (pHFAC) cells and a human fetal adrenal
cell line NCI-H295A were used to understand how nicotine inhibits
StAR expression and cortisol production. We have identified a nicotine-
sensitive CpG site of methylation at a potential Pax6 binding motif in
the StAR promoter that may down-regulate StAR expression. This
study has uncovered a novel potential target that will be helpful for
development of early diagnosis and therapeutics for IUGR-related dis-
eases or disorders.
Materials and methods
Chemicals and reagents. Nicotine (N3876), collagenase I, deoxyri-
bonuclease I (DNase I), selenium/insulin/transferrin (SIT) and bovine
serum albumin (BSA) were obtained from Sigma-Aldrich Corp (St
Louis,Mo). Dulbecco'sModified Eagle'sMediumandHam's F12Medium
(DMEM/F12), Hanks balanced salt solution, RPMI-1640, Opti-MEM® I
Reduced Serum Medium, fetal bovine serum (FBS), penicillin, strepto-
mycin, and amphotericin B were purchased from Invitrogen (Carlsbad,
Calif). All primers were synthesized by Integrated DNA Technologies
(Coralville, Iowa). All chemicals and reagents were of analytical grade.
Isolation of primary human fetal adrenal cortex cells (pHFAC) and cell
culture. The pHFAC cells, consisting mainly (90%–95%) of fetal
zone cells, were isolated from clinically dead fetuses without cigarette
smoke and tobacco exposure as previously described by our group
(Wang et al., 2006). Use of human material was approved by the
Human Medical Ethics Committee of Wuhan University. The gland
was decapsulated to remove most of the definitive zone, and the
remaining fetal zone was minced with fine scissors and incubated in
the digestion mixture at 37 °C for 30 minutes with gentle shaking.
The digestion mixture consisted of 10 mL of Hanks balanced salt solu-
tion containing 1 mg/mL collagenase I, 5 mg/L DNase I, and 5 mg/mL
BSA. After the cells were dispersed using a pipette, they were washed
with DMEM/F12 media, filtered through a 100-μm strainer (Millipore,
Bedford, Mass), and counted with a hemacytometer. For each adrenal
gland, approximately 20 million pHFAC cells were obtained immedi-
ately after enzymatic digestion, and about 90% of the isolated cells
were viable as determined with trypan blue exclusion. The cells
were plated in 6-well polystyrene plates (Corning, NY) at 106 cells
per well in 2 mL cell culture media: DMEM/F12 with 20% heat-
inactivated FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, and
250 ng/mL amphotericin B. Plates were placed in a humidified incu-
bator with 10% CO2 at 37 °C. Two days later, the mediumwas replaced
by adding fresh medium containing nicotine (1–100 μM) and the cul-
ture continued for 24 hours. Then the medium and the cells were
harvested and stored at −80 °C for future use.
NCI-H295A cell culture and drug treatment. An adherent subline of
human adrenocortical carcinoma cells (NCI-H295A) is the best
model available for experimental research on human fetal adrenal,
and produces the steroids and regulates the enzymes of human adre-
nal steroidogenesis in a manner similar to that of human fetal adrenal
cells (Dardis and Miller, 2003; Kian Tee et al., 2011). NCI-H295A cells
were kindly provided as gift by Prof. W.L. Miller and employed for all
the mechanistic experiments of this study. Standard medium for NCI-
H295A cells is RPMI-1640 supplemented with 2% FBS, 0.1% SIT and
penicillin/streptomycin (Dardis and Miller, 2003). At 80% confluence,
NCI-H295A cells were starved with serum-free media overnight, and
then were treated with nicotine at the doses and for the days indicat-
ed. In some experiments, 100 μM nicotine treatment was withdrawn
10 days later and the cells were continually subcultured for up to 0,
15, and 30 days (or 0, 5, and 10 passages), respectively. The mRNA
and genomic DNA were isolated and stored at −80 °C for the future
analysis.
Human cortisol and dehydroepiandrosterone (DHEAS) production.
Culture medium collected from pHFAC cells and NCI-H295A cells with
or without nicotine treatment was used to detect the levels of cortisol
and DHEAS. Cortisol level was measured by human cortisol ELISA kit
obtained from DRG Instruments GmbH (Marburg, Germany) following
the manufacturer's protocol. DHEAS levels were assayed using human
DHEAS radioimmunoassay kit from NovaTec Immundiagnostica
GmbH (Dietzenbach, Germany) following the manufacturer's protocol.
Hormone levels in all samples were measured simultaneously to avoid
inter-assay variability.
RNA extraction and RT-PCR. Total RNAswere extracted using RNeasy
Mini kit obtained fromQiagen (Hiden, Germany) following the protocol
provided by the manufacturer. Extracted RNA was reverse transcribed
to cDNA with the SuperScript™ II RNase H Reverse Transcriptase (Invi-
trogen, Carlsbad, Calif). Synthesized cDNA was amplified by Platinum
TaqPCRx DNA Polymerase (Invitrogen, Carlsbad, Calif). Specific primers
for StAR: StAR forward TGAGCAGAAGGGTGTCATCAGG; StAR reverse
CGCAGGTGGTTGGCAAAATC. PCR conditions for StAR were 30 s at
94 °C, 30 s at 59 °C, 25 s at 68 °C for 25 cycles; Specific primers for
Pax6 (paired box 6): Pax6 forward GTGCGACATTTCCCGAATTCTG;
Pax6 reverse GCCAGGTTGCGAAGAACTCTG. PCR conditions for Pax6
were 30 s at 94 °C, 30 s at 56 °C, 30 s at 68 °C for 40 cycles. The expres-
sion of a housekeeping gene, glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH), was served as internal controls.
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Genomic DNA extraction and sodium bisulfite modification. Genomic
DNA samples prepared using DNeasy Blood & Tissue kit (Qiagen,
Hiden, Germany) were subjected to bisulfite modification using EZ
DNA methylation-direct kit (Zymo research corporation, Orange,
CA) according to the manufacturer's instruction. The basic principle
of bisulfite modification of DNA is that in the bisulfite reaction, all
unmethylated cytosines are deaminated and sulfonated, converting
them to thymines, while methylated cytosines (5-methylcytosines)
remain unaltered (Lorente et al., 2008). Modified DNA was used im-
mediately or stored at −80 °C for future use within 6 months.
Bisulfite Sequence PCR (BSP). The methylation status of StAR gene
was quantitated using Bisulfite Sequence PCR (BSP) as described pre-
viously (Habano et al., 2011). The bisulfite-treated genomic DNA was
amplified by Takara's Ex Taq™ DNA Polymerase purchased from
Invitrogen (Carlsbad, Calif) using two primers StAR-1 and StAR-2
which cover almost the entire CpG rich region of the proximal
StAR promoter. Primers of StAR-1 (−719 bp to−280 bp): forward
ACGACTCACTCTAGGGATGGTTTTTATTGTTTGGTAAATATTTT and reverse
AAAAAAAAAAAACTTCCCTTAACCAAAC; StAR-2 (−9 bp to +402 bp):
forward ACGACTCACTCTAGGGGGTTAAAGTAGTAGTGTGAGGTAAT and
reverse CAAAATTAAATAACCTAAACCTCATCC. The bisulfite PCR products
were sequenced for 6–9 reactions by Biomedical Instrumentation
Center (USUHS, USA). Methyl+ACGACTCACTCTAGGG as an additional
sequence primer.
Methylation specific PCR (MSP). The methylation status of the single
CpG (−377 bp) within StAR promoter was evaluated by MSP as de-
scribed previously (Csepregi et al., 2010). In brief, DNA was subjected
to bisulfite modification and was amplified using two different primer
pairs specific to either methylated or unmethylated sequences, respec-
tively. Primer sequences for methylated reactions were forward
primer: ATGGTTTTTATTGTTTGGTAAATATTTT and reverse primer:
CAAAATAAACAAATCACTTAAAATCAAACG, which amplified a 373 bp
product. Primer sequences for unmethylated reactions were forward
primer: ATGGTTTTTATTGTTTGGTAAATATTTT and reverse primer:
CCAAAATAAACAAATCACTTAAAATCAAACA, which amplified a 374 bp
product. CpGenome™ Universal Methylated DNA (Q-Biogene,
Heidelberg, Germany) was used as positive control. PCR amplification
was performed by Takara's Ex Taq™ DNA Polymerase (Invitrogen,
Carlsbad, Calif). Methylation specific PCR products were analyzed by a
2% agarose gel and stained with ethidium bromide.
Pax6 gene silence (siRNAs). Small interfering RNAs (siRNAs) to the
human Pax6, Pax6 siRNA (h) and the control siRNA-Awere purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Transfection was
carried out using the Lipofectamine™ 2000 transfection reagent
(Invitrogen, Carlsbad, Calif) according to the manufacturer's instruc-
tion. In brief, NCI-H295A cells were grown to 30% confluence in com-
plete medium without antibiotics in 60-mm plates. 200 pmol siRNAs
resuspended in 500 μL Opti-MEM® I Reduced Serum Medium with-
out serum was diluted at 1:50 in volume ratio with Opti-MEM® I
Reduced Serum Medium. After 5 minutes of incubation at room tem-
perature, the diluted oligomer was combined with the diluted
lipofectamine™ 2000 following the manufacturer's instruction. After
incubation for 20 minutes at room temperature, the Lipofectamine™
2000 complexes were added to each well containing cells and medi-
um. Incubate the cells at 37 °C in a CO2 incubator for 72 hours. The
transfection of siRNAs was repeated once before the cells were
harvested for analysis.
Luciferase activity assay. Luciferase assay kit and pGL4 luciferase
reporter vector were purchased from Promega. CpG Methyl-
transferase M.SssI was purchased from New England Biolab. DNA se-
quence (GCTGGTCTCGAACGCCTGACCTCAAGTGATCTG) in the human
StAR gene promoter that contains the HD binding motif of Pax6 was
subcloned into pGL4 luciferase reporter vector at Nhe I and Hind III
sites. This reporter vector has a minimal promoter that ensures min-
imal expression of luciferase in the absence of a specific transcription
activator. Luciferase activity was assayed by following the man-
ufacturer's protocol with the EnVision system (PerkinElmer). CpG
methylation of the StAR/Pax6 reporter was generated by incubation
of the reporter plasmid with M.SssI by following the enzyme instruc-
tion. The reaction induces complete CpG methylation of the reporter
plasmids. The methylated reporter was then purified with MiniPrep
DNA kit (Qiagen). 2×105 NCI-H295A cells/well were seeded in 24-well
plate one day before transfection with Lipofectamine™ 2000 in growth
RPMI 1640 medium containing 2% FBS and 1% ITS. For each well, 0.4 μg
of StAR/Pax6 reporter with either 0.4 μg Pax6 or 0.4 μg of empty vector
(mock) were mixed and then utilized for co-transfection. Two days
after transfection, the cells were harvested for luciferase activity assay.
All experiments were performed in duplicates.
Immunoprecipitation and western blot analysis. Cells were rinsed
with ice-cold PBS, and then lysed for 30 minutes at 4 °C in RIPA lysis
buffer (25 mmol/L HEPES pH 7.5, 50 mmol/L NaCl, 1% NP40,
2.5 mmol/L EDTA, 10% glycerol, 1% triton X-100) containing protease
inhibitors (2 mmol/L NaF, 2 mmol/L sodium orthovanadate, 2 mmol/L
sodium pyrophosphate, and 1 mmol/L protein inhibitor). After centri-
fugation at 15,000 g for 15 minutes, the resulting supernatant
was collected and used for SDS polyacrylamide gel electrophoresis
(SDS-PAGE) and western blotting analysis. Protein concentration
was estimated with a Bio-Rad protein assay kit. For direct immuno-
blotting, aliquots of lysate were mixed with 5×loading buffer con-
taining 2-mercaptoethanol and maintained at 100 °C for 10 minutes
before loading on 10% SDS-PAGE. Following SDS-PAGE separation,
proteins were transferred to PVDF membrane. Membranes were
blocked in TBST containing 5% (w/v) non-fat milk and dried for
1 hour at room temperature. Membrane strips were incubated over-
night at 4 °C with primary antibodies at the following dilutions:
StAR (Santa Cruz Biotechnology, Santa Cruz, CA) 1:200, P450scc
(Santa Cruz Biotechnology, Santa Cruz, CA) 1:200, GAPDH (Cell Sig-
naling Technology, Beverly, MA) 1:1000. Following extensive wash-
ing, membrane strips were incubated in the dark for 1 hour with a
fluorescent secondary antibody at 1:5000 dilutions in blocking solu-
tion containing 0.1% Tween-20. The fluorescent secondary antibodies
were Alexa Fluor 680 goat anti-mouse Molecular Probes (Rockland
Immunochemicals, PA), Alexa Fluor 800CW goat anti-rabbit Molecu-
lar Probes (Rockland Immunochemicals, PA). Images were acquired
with the Odyssey Infrared Imaging System (LI-COR, Biosciences, NE,
USA) and analyzed by the software program as speciWed in the Odys-
sey Software Manual.
Statistical analysis. All the values are expressed as mean±standard
error of the mean (S.E.M.). Statistical Package for Social Sciences (SPSS
11.5) was used for data analysis. Differences among multiple groups
were assessed using analysis of variance (ANOVA). Differences in pro-
portions were examined with Chi-square test or Fisher's Exact Test. A
probability value of Pb0.05 was considered statistically significant.
Results
Nicotine decreases cortisol/DHEAS production in pHFAC cells
To determine the direct effect of nicotine on the fetal adrenal, the
pHFAC cells were treated with nicotine by addition to the culture me-
dium at various concentrations for 24 hours. Nicotine exhibited dose-
dependent inhibition of accumulation of cortisol and DHEAS in medi-
um (Fig. 1). Nicotine at 10 μM suppressed the production of cortisol
and DHEAS by 17.1% (Pb0.01) and 18.8% (Pb0.05) respectively,
whereas at 100 μM, suppression was 35.7% (Pb0.01) and 57.6%
(Pb0.01), respectively.
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The decrease of cortisol/DHEAS production associates with suppression of
StAR/P450scc expression in nicotine-treated pHFAC cells
Fig. 2A shows that the mRNA expression of fetal adrenal StAR had a
tendency of dose-dependent decrease. Nicotine at 100 μM decreased
the mRNA expression of StAR by 61.2% (Pb0.05). Nicotine at 100 μM
also decreased P450scc mRNA expression by 64.3% (Pb0.05), although
a tendency of dose-dependent decrease was not seen (Fig. 2B). More-
over, the protein expression of fetal adrenal StAR and P450scc as
shown in Fig. 2Cwas in agreementwith the results ofmRNA expression.
Nicotine at 100 μM decreased the StAR and P450scc protein expression
by 70.0% (Pb0.01, Fig. 2D) and 55.7% (Pb0.05, Fig. 2E), respectively.
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Fig. 1. Effects of nicotine (0 to 100 μM) on cortisol and dehydroepiandrosterone (DHEAS) levels in primary human fetal adrenal cortex cells. Cortisol (A) and DHEAS (B) levels after
nicotine exposure at different concentrations (0, 1, 10, and 100 μM) for 24 hours are expressed as mean±S.E.M. n=6. ⁎Pb0.05, ⁎⁎Pb0.01 vs their corresponding controls.
Fig. 2. Effects of nicotine (0 to 100 μM) on acute regulatory protein (StAR) and cytochrome P450 cholesterol side chain cleavage (P450scc) expression in primary human fetal ad-
renal cortex cells. A. StAR mRNA expression after nicotine treatment for 24 hours; B. P450scc mRNA expression after nicotine treatment for 24 hours; C. Western blot detection of
protein expression of StAR and P450scc after nicotine exposure for 24 hours; D: Quantitative presentation of StAR protein expression. Data are expressed as mean±S.E.M. n=3.
⁎Pb0.05, ⁎⁎Pb0.01 vs their corresponding controls.
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The nicotine-induced alterations are reproducible in NCI-H295A cells
Chronic treatment of NCI-H295A cells with nicotine resulted in
lower levels of cortisol in a time- and concentration-dependent man-
ner, than in the corresponding controls (Fig. 3A). Nicotine decreased
cortisol level by 16% (Pb0.05) and 21% (Pb0.05) at 50 μM for 3 and
5 days (Fig. 3A), and by 17.1% (Pb0.05), and 32.1% (Pb0.01) at 25
and 100 μM for 5 days, respectively, as compared with the control
(Fig. 3B). These data in NCI-H295A cells reproduced nicotine-induced
inhibition of accumulation of cortisol and DHEAS in medium.
Consistent to the decrease of cortisol level, nicotine treatment also
inhibited the expression of StAR in a dose-dependent manner (Fig. 4).
Chronic treatment of NCI-H295A cells with 100 μM nicotine for 5, 6, 7
and 8 days significantly decreased StAR mRNA expression by 17.4%,
34.8%, 45.7% and 50.0% (PN0.05 or Pb0.05) respectively, as compared
with their corresponding control treatments (Fig. 4A). On day 3, nic-
otine at 100 μM had already caused a 19.6% decrease of StAR mRNA
expression, equivalent to the magnitude seen on day 5. When various
concentrations were applied, treatment with nicotine at 50 and
100 μM for 7 days decreased StAR mRNA expression by 42.4%
(Pb0.01) and 48.5% (Pb0.01), respectively (Fig. 4B). In agreement
with the mRNA expression, chronic treatment with 100 μM nicotine
for 7 days decreased StAR protein expression by 44.0% (Pb0.01) as
compared with the control treatment (Fig. 4C).
To determine whether cell proliferation and viability played any
role in the nicotine-induced decreases of StAR mRNA and protein ex-
pression, NCI-H295A cells were treated with nicotine at 1, 10, and
100 μM for 7 days and the cell proliferation/viability was measured
with the MTT assay. The data revealed no significant difference
among various treatments (Fig S1 in supplemental information).
The alteration in StAR expression persists for more than 5 passages after
termination of nicotine treatment
To determine for how long the depressed StAR expression can last
after withdrawal of nicotine from the culture medium, NCI-H295A
cells treated with 100 μM of nicotine for 10 days were continued to
grow in the absence of nicotine for up to 30 days or about 10 pas-
sages. As shown in Fig. 5, the StAR mRNA expression at post-nicotine
day 0 (passage 0), day 15 (passage 5), and day 30 (passage 10) were
decreased by 67.6% (Pb0.01), 46.0% (Pb0.01) and 10.7%, respectively,
as compared with their corresponding control. These data revealed an
almost linear daily recovery (1.4%–1.9%) of the depressed StAR mRNA
expression after termination of the nicotine treatment. In theory, a
full recovery might be achievable on day 35 after the nicotine treat-
ment is terminated.
A single CpG site of nicotine-sensitive methylation is identified in StAR
promoter
To determine whether CpG methylation is involved in the nico-
tine-induced decrease of StAR expression, the proximal promoter of
the human StAR gene was selected for methylation analysis. We
first analyzed human StAR gene with a web promoter scan service
(http://www-bimas.cit.nih.gov/molbio/proscan/) and found that it
has one promoter. As shown in Fig S2 (supplemental information),
the StAR promoter and the adjacent regions contain many CpG dinu-
cleotides, potential sites of DNA methylation, but no CpG islands. The
methylation status within such a region (nt −719 to −280 and −9
to 402) was detected using BSP and MSP assays. Fig. 6A shows that
the three CpG sites at nt−682,−441, and−381 of the promoter re-
gion are methylated in the absence of nicotine treatment. Treatment
with 100 μM nicotine for 7 days resulted in a substantially increased
frequency of methylation of a single CpG site at nt−377, but little ef-
fect on the methylation status of the three CpG sites. No significant
changes were seen in NCI-H295A cells treated with 25 μM of nicotine
for 7 days. No CpG methylation was detected within the region of−9
to 402 bp in both the absence and presence of nicotine treatment
(data not shown).
Consistently, the frequency of the single point methylation at nt
−377 increased in a time-dependent manner when the cells were
treated with 100 μM nicotine (Fig. 6B). On days 3 and 7, 100 μM nic-
otine increased the frequencies of this site methylation by 2.6 fold
(50%, or 30.8% above the basal frequency) and 4.8 fold (91.8%, or
72.6% above the corresponding basal frequency), respectively, as
assayed using the MSP method (Fig. 6B). However, nicotine at a
lower concentration (25 μM) for 7 days did not increase the frequen-
cy of this point methylation (Fig. 6C), suggesting that this nicotine-
sensitive CpG site is more sensitive to nicotine dose than the treat-
ment duration. Interestingly, a basal frequency (19.2%) of the point
methylation in the absence of nicotine treatment was also observed
(Figs. 6B and C). This is consistent to the result obtained using the
BSP assay (Fig. 6A).
The single site methylation persists for more than 5 passages after
termination of nicotine treatment
We have shown in Fig. 5 that the suppression of StAR expression
can continue for more than 15 days or 5 passages after the nicotine
treatment is terminated. To determine whether the nicotine-sensitive
point methylation at nt −377 in StAR promoter undergoes a similar
time course as StAR expression does, the NCI-295A cells pre-treated
with 100 μM nicotine for 10 days were cultured for 5 and 10 more
Fig. 3. Effect of nicotine chronic treatment on cortisol level in NCI-H295A cells. A. Cortisol produced by 3×104 cells treated with 50 μM nicotine for different days (3 and 5 days)
were detected with ELISA kit. B. Cortisol produced by 4×103 cells treated with different concentrations (0, 25, 50, and 100 μM) of nicotine for 5 days were detected with ELISA
kit. Data are expressed as mean±S.E.M. n=5. ⁎Pb0.05, ⁎⁎Pb0.01 vs control.
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passages (equivalent to about 15 and 30 more days, respectively) in
the absence of nicotine treatment. At the end of passage 5 and 10,
the genomic DNA samples were isolated and the point methylation
was examined using the MSP assay. Fig. 7 shows that the frequency
of the single point CpG methylation at nt −377 remained high level
(85.5%) over the first 5 passages (15 days) and dropped to 45% over
the second 5 passages after treatment with nicotine for 10 days.
These MSP results were largely consistent to BSP data on the methyl-
ation frequency (data not shown).
Pax6 promotes StAR gene expression
Human cDNA array data showed that nicotine treatment could not
alter the expression of Pax6 in pHFAC cells (data not shown). To de-
termine whether Pax6 binding could promote the StAR gene expres-
sion and the methylation at nt −377 could block Pax6 binding, the
siRNA approach and luciferase activity assay were employed.
Figs. 8A and B show that the two consecutive transfections of NCI-
H295A cells with Pax6 siRNA on day 1 and day 3 decrease Pax6
mRNA expression by more than 98% as assayed on day 6. As expected,
the StAR mRNA expression is also decreased by about 64.2% (Pb0.01)
in the absence of nicotine treatment. This magnitude of decrease in
StAR expression caused by Pax6 knock-down is even greater than
that caused by treatment with 100 μM nicotine for 7 days. Fig. 8C
shows that pre-treatment of the StAR/Pax6 reporters with M.SssI sig-
nificantly reduced the luciferase activities in both absence (62%) and
presence (71%) of Pax6 expression (Pb0.01), suggesting that CpG
methylation in the binding motif of Pax6 regulates StAR expression.
Expression of Pax6 significantly increased luciferase activities to 4
and 2.9 folds from baseline (mock) for the StAR/Pax6 reporters pre-
treated with and without M.SssI, respectively (Pb0.01), suggesting
that Pax6 activates StAR gene expression by binding to the glucagon
G3-like motif (CGCCTGA) and the methylation of this site partially
blocks StAR expression.
Fig. 4. Effect of chronic nicotine treatment on acute regulatory protein (StAR) expression in NCI-H295A cells. A. StAR mRNA expression after 100 μM nicotine exposure for different
days. B. StAR mRNA expression after different doses of nicotine treatment for 7 days. C. StAR protein expression after 100 μM nicotine treatment for 7 days. D. Quantitative presen-
tation of StAR protein expression. Data are expressed as mean±S.E.M. n=3. ⁎Pb0.05, ⁎⁎Pb0.01 vs control.
Fig. 5. Expression of acute regulatory protein (StAR) mRNA in NCI-H295A cells after withdrawal of nicotine treatment. A. After chronic treatment of NCI-H295A cells with 100 μM
nicotine for 10 days, nicotine treatment was stopped and the cells were further cultured for up to 5, 10 passages. Then the StAR mRNA expression was detected using semi-quan-
titative RT-PCR; B. Quantitative presentation of StAR mRNA expression. Data are expressed as mean±S.E.M. n=3. ⁎⁎Pb0.01, ##Pb0.01 vs their corresponding controls.
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Discussion
StARmediates the initial and rate-limiting step in adrenocortical ste-
roidogenesis and plays a critical role in themaintenance of normal preg-
nancy and promotion of fetal growth (Ramanjaneya et al., 2011; Stocco,
2001). In the present study, we found that nicotine treatment inhibited
StAR/P450scc expressions and cortisol production in both pHFAC cells
and NCI-H295A cells. A correlation between cortisol production and
StAR expression suggests that StAR is critical and sensitive in regulating
steroidogenesis in the presence of nicotine. Moreover, the expression of
StAR remained suppressed over 15 days (5 passages) after termination
of nicotine treatment, which suggests the hereditability of nicotine-in-
duced inhibition of StAR gene expression.
The nicotine concentration of 100 μM used in this cell culture study
is much higher than the reported plasma levels of cigarette smokers,
ranging from 0.1 to 0.6 μM (Russell et al., 1975; Satta et al., 2008). Nic-
otine levels in fetal circulation, amniotic fluid, and fetal tissues can be
higher largely due to free penetration of placenta and lipophilic accu-
mulation of nicotine over the course of 10-month pregnancy, and low
enzymatic activity of fetal CYP2A6 (Dempsey et al., 2000; Lambers
and Clark, 1996; Machado Jde et al., 2011). Thus, much higher concen-
trations up to 100 or even 300 μM have been utilized in many short-
term (several days) in vitro cell culture studies (Fang and Svoboda,
2005; Kawakita et al., 2008; Klapproth et al., 1998; Klettner et al.,
2011; Laytragoon-Lewin et al., 2011; Naha et al., 2009; Papaioannou
et al., 2011; Serres and Carney, 2006). However, interpretation of
these results generated from in vitro studies should be cautious in the
context of in vivo conditions. Future study will be necessary to deter-
mine if the CpGmethylation at the Pax6 bindingmotif of StAR gene pro-
moter would also occur in smoking humans with typically long term
exposure at physiologically relevant plasma levels.
StAR expression is tightly regulated at multiple levels including
transcriptional, post-transcriptional, translational, and even post-recep-
tor levels (Stocco et al., 2005; Zhao et al., 2005). In this study, we have
demonstrated that a single CpG site methylation at nt −377 of StAR
promoter associates highly with suppression of the gene expression.
This CpG is sensitive to nicotine treatment.We also noticed that this sin-
gle CpG methylation appeared on day 3 of 100 μM nicotine treatment
and before the decrease of StAR mRNA expression, suggesting that the
single CpG methylation is one of the causes for attenuation of expres-
sion of the StAR gene. Recently, more and more literatures support
the viewpoint that single CpG site methylation can play an important
A B
C
Fig. 6. Nicotine-induced changes in methylation status of acute regulatory protein (StAR) gene promoter (nt−719 to−280) in NCI-H295A cells detected with bisulfite sequence
PCR (BSP) and methylation specific PCR (MSP) methods. A. Methylation map of StAR promoter in NCI-H295A cells treated with 25, 100 μM nicotine for 7 days detected with BSP.
B. Methylation frequency of StAR promoter at nt−377 single site in NCI-H295A cells treated with 100 μMnicotine for 3, 7 days detected with MSP. C. Methylation frequency of StAR
promoter at nt −377 single site in NCI-H295A cells treated with 25, and 100 μM nicotine for 7 days detected with MSP. Data are expressed as mean±S.E.M. n=3. ⁎Pb0.05,
⁎⁎Pb0.01 vs their corresponding controls.
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Fig. 7. Prolonged methylation status of nt −377 single site in acute regulatory protein
(StAR) promoter in the NCI-H295A cells after withdrawal of nicotine treatment. After
chronic treatment of NCI-H295A cells with 100 μM nicotine for 10 days, nicotine treat-
ment was stopped and the cells were further cultured for up to 5, 10 passages. Then the
methylation frequency at nt−377 single site in StAR promoter was detected using MSP.
Data are expressed as mean±S.E.M. n=3. ⁎Pb0.05 vs their corresponding controls.
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role on regulation of gene expression. Expression of hypoxic marker CA
IX is regulated by site-specific DNA methylation and is associated with
the histology of gastric cancer (Nakamura et al., 2011). Methylation of
a single intronic CpG mediates expression silencing of the PMP24
gene in prostate cancer (Zhang et al., 2010b). A variant in the CHEK2
promoter at a methylation site relieves transcriptional repression and
confers reduced risk of lung cancer (Zhang et al., 2010a). Although the
mechanism remains largely unknown and poorly explored, reports
have shown that single site methylation requires additional transcrip-
tion factors or methyl binding domain-containing proteins for regula-
tion of gene expression (Kim et al., 2003; Kitazawa and Kitazawa,
2007; Zhang et al., 2010a). The obvious correlation between nicotine-in-
duced alterations in StAR expression and the single CpG sitemethylation
suggested that methylation-sensitive factor binding and competition
binding between transcription factors to CpG-containing recognition
motifs are possible mechanisms for the regulation of growth-related
gene expression both during development and in the mature organism
(Kitazawa and Kitazawa, 2007).
Likemany genes, the expression of StAR can be regulated by a variety
of transcription factors. These transcription factors include steroidogenic
factor-1 (SF-1), CCAAT/enhancer binding proteins (C/EBP), sterol regula-
tory element-binding proteins (SREBPs), and GATA-4 (Stocco et al.,
2005). Pax6 is a critical transcription factor in the development of eye,
pancreas, and central nervous system and variations in the Pax6 binding
motif are reported (Grapp et al., 2009; Umeda et al., 2010). Studies have
shown that Pax6 binds the glucagon-G3 promoter consensus
(CGCCTGA) (Grapp et al., 2009). Pax6 has two DNA binding domains,
the amino-terminal paired domain (PD) followed by a homeodomain
(HD). It is the PD domain that binds the glucagon-G3 consensus
CGCCTGA (Grapp et al., 2009). Interestingly, the identified single CpG
site of nicotine-sensitive methylation (nt −377) is part of the gluca-
gon-G3 consensus. In this study, we identify using bioinformatic analysis
(Fig S3 in supplemental information) and siRNA approach that nicotine
causes methylation of the single CpG site at which the potential Pax6
binding motif is positioned. However, nicotine does not alter much the
Pax6 expression in pHFAC cells (unpublished data). The luciferase activ-
ity assays validate the notion that Pax6 increases StAR gene expression
by binding to the glucagon G3-like motif (CGCCTGA). These data with
M.SssI pretreated reporter also confirm that Pax6 binding to StAR pro-
moter is sensitive to CpG methylation. Similar to methylation-sensitive
restriction endonuclease AscI, Pax6may be amethylation-resistant tran-
scription factor that binds only to its unmethylated motifs (Dai et al.,
2002). CpG methylation at the minimal binding motif of Pax6
(CGCCTGA) caused inhibition of StAR expression to certain degree, but
not complete abolishment. Althoughmethylation at−377 CpG site cor-
relates well with the suppressed StAR expression and reporter luciferase
assay validates the role of Pax6 in regulating StAR expression, the
suppression of StAR expression induced by nicotine treatment may
also involve other unidentified mechanisms. Interestingly, using bioin-
formatic analysis, we also identify that the Pax6 motif identical to the
glucagon-G3 consensus (CGCCTGA) in the StAR promoter is also present
in other genes including component genes consisting of hypothalamic–
pituitary–adrenal (HPA) axis, such as corticotrophin-releasing hormone
receptor type-1 (CRHR1), melanocortin 2 receptor (MC2R), and gluco-
corticoid receptor (GR). Whether Pax6 binds to these genes consisting
of HPA axis and whether nicotine induces single CpG methylation in
these gene motifs are unclear. However, nicotine may alter intrauterine
programming of HPA axis by interfering with the expression of these
component genes, to induce collectively IUGR and onset of adult diseases
or disorders (Simard et al., 2010).
Fig. 8. Pax6 increased acute regulatory protein (StAR) gene expression by binding to the glucagon G3-like motif (CGCCTGA) in StAR promoter. A. Effect of Pax6 siRNAs on StAR
mRNA expression. NCI-H295A cells were transfected with Pax6 siRNAs in lipofectamine 2000 for 72 hours, and then the transfection was repeated once. Then StAR and Pax6
mRNA expression were detected on day 6 after initial transfection using RT-PCR; B. Quantitative presentation of StAR mRNA expression. Data are expressed as mean±S.E.M.
n=3. ⁎⁎Pb0.01 vs control. C. Luciferase activity assay of the StAR/Pax6 reporter. NCI-H295A cells were co-transfected with StAR/Pax6 reporter and Pax6 or empty vector
(mock) in lipofectamine 2000 for 48 hours. The cells were harvested for luciferase activity assay. Data are expressed as mean±S.E.M. n=3. 5 m-StAR, the StAR/Pax6 reporter pre-
treated with M.SssI; ⁎⁎Pb0.01 vs their corresponding mocks; ##Pb0.01 vs their corresponding unmethylated StAR/Pax6 reporters.
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Our results showed the nicotine-induced long-term suppression
of StAR expression over 15 days (5 passages) after termination of
the treatment largely matched up with the demethylation pattern of
the single site methylation at nt −377 of the StAR promoter, which
suggests that the DNA methylation mechanism induced by nicotine
are heritable. Identification and correction of critical epigenetic mod-
ification may hold key for developing early diagnosis and treatment
of some adult diseases or disorders (Deng et al., 2010). It is well
established that CpG methylation in the proximal promoter inhibits
the gene expression (Mund and Lyko, 2010). In our studies, nico-
tine-induced CpG methylation of Pax6 binding motif in StAR promo-
tor reduces the StAR gene expression and cortisol production. These
compelling data suggest that this nicotine-sensitive CpG methylation
site at Pax6 binding motif in StAR promoter may be useful for the
early diagnosis and treatment of prenatal nicotine exposure-related
adult diseases or disorders.
In summary, in this study, we not only demonstrated that nicotine
inhibited StAR/P450scc expressions and cortisol production in both
pHFAC cells and NCI-H295A cells, but also for the first time identified
a single nicotine-sensitive CpG methylation site at the Pax6 binding
motif in StAR promoter that prevent Pax6 from binding the motif and
down-regulate StAR gene expression. The close correlation between
sustained suppression of StAR expression and persistent CpG methyla-
tion at nt−377 after termination of nicotine treatment provided an in-
heritable epigenetic mechanism for nicotine-induced intrauterine
programming of HPA axis and onset of adult diseases or disorders.
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